Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2020-02-04

FDA Approved: ARIPIPRAZOLE — Supplemental Application (Alembic Pharmaceuticals Inc.)

View source ↗

Summary

FDA approved Alembic Pharmaceuticals' supplemental application to market a generic ARIPIPRAZOLE under an ANDA.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ARIPIPRAZOLE (Aripiprazole)

Snippet

SUPPL AP for ARIPIPRAZOLE (ARIPIPRAZOLE)